Format

Send to

Choose Destination
Atherosclerosis. 2019 Jul;286:1-6. doi: 10.1016/j.atherosclerosis.2019.04.222. Epub 2019 Apr 20.

The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events.

Author information

1
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
2
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Medical Central Laboratories, Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein.
3
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Division of Angiology, Swiss Cardiovascular Center, University Hospital of Bern, Bern, Switzerland.
4
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Medical Central Laboratories, Feldkirch, Austria.
5
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
6
Medical Central Laboratories, Feldkirch, Austria.
7
Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Division of Angiology, Swiss Cardiovascular Center, University Hospital of Bern, Bern, Switzerland; Drexel University College of Medicine, Philadelphia, PA, USA. Electronic address: heinz.drexel@extern.insel.ch.

Abstract

BACKGROUND AND AIMS:

The recently identified adiponectin paralogue C1q and tumor necrosis factor-related protein 1 (CTRP1) has been associated with obesity-linked disorders and coronary atherosclerosis. So far, the impact of circulating CTRP1 on the incidence of future cardiovascular events is unclear. Therefore, we aimed at investigating the association between CTRP1 and future cardiovascular risk.

METHODS:

We measured CTRP1 serum levels in 539 patients undergoing coronary angiography for the evaluation of established or suspected stable coronary artery disease (CAD). Prospectively, we recorded major adverse cardiovascular events (MACE), defined as the incidence of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke over a follow-up period of 8 years.

RESULTS:

At baseline, obesity, the metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease were significantly associated with increased CTRP1 (all p-values ≤0.001). Prospectively, MACE rates were lowest in the first quartile (15.3%) and increased over the second (23.7%) to the third and fourth quartile (each 29.0%; ptrend = 0.008). Moreover, after multivariable adjustment, CTRP1 was significantly associated with future MACE, with adjusted HRs of 1.83 [1.04-3.23]; p=0.037, 2.16 [1.25-3.75]; p=0.006, and 1.80 [1.03-3.15]; p=0.038, for CTRP1 quartiles two, three and four, respectively, when compared to quartile one.

CONCLUSIONS:

We conclude that high serum levels of CTRP1 are significantly associated with future MACE.

KEYWORDS:

Adipokine; CTRP1; Major adverse cardiovascular events; Prospective study; Risk factor

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center